Evento
Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer
Bruni, Sofia
; Mauro, Florencia Luciana
; de Martino, Mara
; Roldán Deamicis, Agustina; Mercogliano, María Florencia
; Elizalde, Patricia Virginia
; Schillaci, Roxana






Tipo del evento:
Reunión
Nombre del evento:
AACR Virtual Annual Meeting 2020
Fecha del evento:
22/06/2020
Institución Organizadora:
American Association for Cancer Research;
Título de la revista:
Cancer Research
Editorial:
American Association for Cancer Research
ISSN:
0008-5472
e-ISSN:
1538-7445
Idioma:
Inglés
Clasificación temática:
Resumen
Lapatinib (LAP), a dual EGFR/HER2 tyrosine kinase inhibitor, is used as second-line therapy in women with HER2+ breast cancer (BC), but less than 25% of the patients achieve an objective response. An alternative therapeutic approach is needed to overcome LAP resistance in women with metastatic HER2+ BC, particularly in patients with central nervous system (CNS) metastasis where large biological molecules are not effective.
Palabras clave:
TNF
,
BREAST CANCER
,
LAPATINIB
,
HER2
Archivos asociados
Licencia
Identificadores
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer; AACR Virtual Annual Meeting 2020; en línea; Estados Unidos; 2020; 1913-1913
Compartir
Altmétricas